Biophytis SA is a biotechnology business based in the US. Biophytis shares (BPTS) are listed on the NASDAQ and all prices are listed in US Dollars. Biophytis employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Biophytis
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BPTS – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Biophytis stock price (NASDAQ: BPTS)Use our graph to track the performance of BPTS stocks over time.
Biophytis shares at a glance
|Latest market close||$6.93|
|52-week range||$6.90 - $18.50|
|50-day moving average||$8.34|
|200-day moving average||$10.32|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.81|
Buy Biophytis shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Biophytis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Biophytis price performance over time
|1 week (2021-10-13)||6.93|
|1 month (2021-09-20)||-12.85%|
|3 months (2021-07-20)||-17.50%|
|6 months (2021-04-20)||-45.09%|
|1 year (2020-10-16)||N/A|
|2 years (2019-10-16)||N/A|
|3 years (2018-10-16)||N/A|
|5 years (2016-10-16)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-38.83%|
|Return on equity TTM||0%|
|Market capitalisation||$87.1 million|
TTM: trailing 12 months
Shorting Biophytis shares
There are currently 1,957 Biophytis shares held short by investors – that's known as Biophytis's "short interest". This figure is 72.6% down from 7,153 last month.
There are a few different ways that this level of interest in shorting Biophytis shares can be evaluated.
Biophytis's "short interest ratio" (SIR)
Biophytis's "short interest ratio" (SIR) is the quantity of Biophytis shares currently shorted divided by the average quantity of Biophytis shares traded daily (recently around 1270.7792207792). Biophytis's SIR currently stands at 1.54. In other words for every 100,000 Biophytis shares traded daily on the market, roughly 1540 shares are currently held short.
To gain some more context, you can compare Biophytis's short interest ratio against those of similar companies.
However Biophytis's short interest can also be evaluated against the total number of Biophytis shares, or, against the total number of tradable Biophytis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biophytis's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Biophytis shares in existence, roughly 0 shares are currently held short) or 0.0002% of the tradable shares (for every 100,000 tradable Biophytis shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biophytis.
Find out more about how you can short Biophytis stock.
Biophytis share dividends
We're not expecting Biophytis to pay a dividend over the next 12 months.
You may also wish to consider:
- CVS Health Corporation (CVS.US) (2.37% forward annual dividend yield)
- UnitedHealth Group Incorporated (UNH.US) (1.28% forward annual dividend yield)
- McKesson Corporation (MCK.US) (0.83% forward annual dividend yield)
Biophytis share price volatility
Over the last 12 months, Biophytis's shares have ranged in value from as little as $6.9 up to $18.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biophytis's is 1.1142. This would suggest that Biophytis's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Biophytis's beta into context you can compare it against those of similar companies.
- CVS Health Corporation (CVS.US): 0.7984
- UnitedHealth Group Incorporated (UNH.US): 0.7905
- McKesson Corporation (MCK.US): 0.8476
Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID-19. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is based in Paris, France. .
Biophytis in the news
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Biophytis to Restate Previously Issued Financial Statements
Biophytis to Restate Previously Issued Financial Statements
Frequently asked questionsWhat percentage of Biophytis is owned by institutions?
Currently 2.508% of Biophytis shares are held by institutions. How many people work for Biophytis?
Latest data suggests 25 work at Biophytis. When does the fiscal year end for Biophytis?
Biophytis's fiscal year ends in December. Where is Biophytis based?
Biophytis's address is: Sorbonne University, Paris, France, 75005 What is Biophytis's ISIN number?
Biophytis's international securities identification number is: US09076G1040
More guides on Finder
How to buy Aura Biosciences (AURA) stock when it goes public
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
How to buy Claros Mortgage Trust (CMTG) stock when it goes public
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
How to buy Evotec SE (EVO) stock when it goes public
Everything we know about the Evotec SE IPO, plus information on how to buy in.
How to buy Delimobil Holding SA (DMOB) stock when it goes public
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
How to buy Blue Water Vaccines (BWV) stock when it goes public
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
How to buy Sonendo (SONX) stock when it goes public
Everything we know about the Sonendo IPO, plus information on how to buy in.
How to buy FlexEnergy Green Solutions (FLXE) stock when it goes public
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
How to buy Stran & Company (STRN) stock when it goes public
Everything we know about the Stran & Company IPO, plus information on how to buy in.
How to buy Kidpik Corp (PIK) stock when it goes public
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
How to buy Nuvectis Pharma (NVCT) stock when it goes public
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
Ask an Expert